Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2002

View Archived Issues

Positive preclinical results reported for Access's mucositis technology

Phase Ib study of BNP-166 successfully completed

Nastech demonstrates potential of nasal delivery of interferon beta-1a for treatment of MS

Oncolytics Biotech's phase I Reolysin study meets primary outcome

NIH licensing opportunity: plant-derived recombinant subunit vaccine candidate against HCV

Specific COX-2 inhibitor effective and safe for Rx of acute dental pain

Inosine demonstrates favorable results in toxicity tests

No dose adjustment required for LY-333531 in renally impaired patients

Milkhaus begins phase II trial of ML-04 as treatment of chronic prostatitis

Sequella Global Tuberculosis Foundation collaborates to develop new TB vaccines

PK/PD of OPC-51803 assessed in patients with urinary incontinence

Potent and selective antagonist of human Y5 receptor identified at Fujisawa

Roche licenses SEP from Gryphon Sciences

Cellegy submits NDS for Rectogesic approval in Canada

Zindaclin launched in the U.K. as once-daily acne treatment

Lipid formulation increases tissue distribution of the antifungal agent SPK-843

Thiazolidinedione derivative may have the potential to prevent chronic pancreatitis

The novel MMP inhibitor SI-27 exhibits antiangiogenic activity in vitro

Gilead seeks U.S. marketing approval of adefovir dipivoxil

PPARgamma agonists reported by Galderma in a recent patent

Takeda researchers identify new GnRH antagonists and their use

Dabur Research Foundation describes new substance P antagonists for the treatment of cancer

Novel group of integrin antagonists presented by 3-Dimensional Pharmaceuticals

Ono scientists present new CB2 receptor agonists

Mitsubishi Pharma discloses new compounds useful for Alzheimer's disease, ADHD, etc.

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...